Morning symptoms in COPD: a treatable yet often overlooked factor

References

• who.int [Internet]. Headquarters Switzerland: World Health Organization; [cited 2017 mar 14]. Available from: http://www.who.int/topics/chronic_obstructive_pulmonary_disease/en/
   Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048.
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–977.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet (London, England). 2012;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• goldcopd.org [Internet]. USA: The Global Initiative for Chronic Obstructive Lung Disease; [cited 2017 Mar 14] ( Available from: http://www.goldcopd.org/)
   Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–238.
   PubMed Web of Science ®Google Scholar
• Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.
   PubMed Web of Science ®Google Scholar
• ginasthma.org [Internet]. USA: The Global Initiative for Asthma (GINA): [cited 2017 Mar 14]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
   Google Scholar
• O’Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin. 2014;30(2):301–314.
   PubMed Web of Science ®Google Scholar
• Globe G, Currie B, Leidy NK, et al. Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD). Health Qual Life Outcomes. 2016;14(1):104.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58(10):855–860.
   PubMed Web of Science ®Google Scholar
• Chan-Thim E, Dumont M, Moullec G, et al. Clinical impact of time of day on acute exercise response in COPD. Copd. 2014;11(2):204–211.
   PubMedGoogle Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee BK, Jung CY, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med. 2012;27(4):426–435.
   PubMed Web of Science ®Google Scholar
• Lange P, Godtfredsen NS, Olejnicka B, et al. Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting. Eur Respir J Suppl. 2016;3:31232.
   Google Scholar
• Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109(5):616–624.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Roche N, Small M, Broomfield S, et al. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. Copd. 2013;10(6):679–686.
   PubMedGoogle Scholar
• Soler-Cataluna JJ, Sauleda J, Valdes L, et al. Prevalence and perception of 24-hour symptom patterns in patients with stable chronic obstructive pulmonary disease in spain. Arch Bronconeumol. 2016;52(6):308–315.
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Cai Q, Mocarski M, et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–586.
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Metting E, Van Der Molen T, et al. Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 2016;26:16040.
   PubMed Web of Science ®Google Scholar
• Jones PW, Watz H, Wouters EF, et al. COPD: the patient perspective. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):13–20.
   PubMedGoogle Scholar
• Espinosa De Los Monteros MJ, Pena C, Soto Hurtado EJ, et al. Variability of respiratory symptoms in severe COPD. Arch Bronconeumol. 2012;48(1):3–7.
   PubMed Web of Science ®Google Scholar
• Kulich K, Keininger DL, Tiplady B, et al. Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstruct Pulmon Dis. 2015;10:79–94.
   PubMed Web of Science ®Google Scholar
• Kuyucu T, Guclu SZ, Saylan B, et al. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks. 2011;59(4):328–339.
   PubMedGoogle Scholar
• van Buul AR, Kasteleyn MJ, Chavannes NH, et al. Association between morning symptoms and physical activity in COPD: a systematic review. Eur Respiratory Review: Official Journal Eur Respir Soc. 2017;26(143):160033.
   Google Scholar
• Miravitlles M, Worth H, Soler-Cataluna JJ, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an Observational Study (ASSESS). Copd. 2016;13(5):561–568.
   PubMedGoogle Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Copd. 2012;9(2):90–101.
   PubMedGoogle Scholar
• Marin JM, Beeh KM, Clemens A, et al. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). Int J Chron Obstruct Pulmon Dis. 2016;11:1425–1434.
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–750.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009;3(4):1–11.
   PubMedGoogle Scholar
• Beier J, Kirsten AM, Mroz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. Copd. 2013;10(4):511–522.
   PubMedGoogle Scholar
• Partridge MR, Miravitlles M, Stahl E, et al. Development and validation of the capacity of daily living during the morning questionnaire and the global chest symptoms questionnaire in COPD. Eur Respir J. 2010;36(1):96–104.
   PubMed Web of Science ®Google Scholar
• Garrow AP, Khan N, Tyson S, et al. The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. Thorax. 2015;70(8):757–763.
   PubMed Web of Science ®Google Scholar
• Palsgrove A, Houghton K, Hareendran A, et al. The development of the early morning symptoms of COPD instrument (EMSCI). PRS51: In Value Health. 2011;14:A233-A510. ​
   Google Scholar
• Jones PW, Quirk FH, Baveystock CM, The St George’s respiratory questionnaire. Respir Med. 1991;850:25–31. discussion 33-27.
   Web of Science ®Google Scholar
• van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13.
   PubMedGoogle Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–354.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, D’Urzo A, Singh D, et al. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17(1):112.
   PubMed Web of Science ®Google Scholar
• Kasteleyn MJ, Bonten TN, Taube C, et al. Coordination of care for patients with COPD: clinical points of interest. Int J Care Coordination. 2015;8(4):67–71.
   Google Scholar
• Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9(1):60.
   PubMedGoogle Scholar